Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 2:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 152,831 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Condition Clear all
Completed No phase listed Observational

Magnetic Resonance Imaging in Patients With Breast Cancer

NCT00610181
View directory record Official record
Conditions
Breast Cancer
Interventions
MRI
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 1, 2015 · Synced Oct 23, 2026, 2:06 PM EDT
Completed Phase 3 Interventional Results available

Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2)

NCT04846881
View directory record Official record
Conditions
Schizophrenia
Interventions
Iclepertin, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 50 Years
Enrollment
611 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
20
States / cities
Bellflower, California • Costa Mesa, California • Long Beach, California + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2025 · Synced Oct 23, 2026, 2:06 PM EDT
Completed Phase 3 Interventional

Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer

NCT00036556
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Atrasentan
Drug
Lead sponsor
Abbott
Industry
Eligibility
19 Years and older · Male only
Enrollment
941 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
94
States / cities
Homewood, Alabama • Anchorage, Alaska • Tucson, Arizona + 73 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2007 · Synced Oct 23, 2026, 2:06 PM EDT
Completed Not applicable Interventional

Infection Rates of Myeloablative Allo SCT Recipients Receiving Neutropenic Diets Versus Non-Neutropenic Diets

NCT01687231
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
Non-neutropenic Diet
Other
Lead sponsor
Duke University
Other
Eligibility
20 Years to 70 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 10, 2013 · Synced Oct 23, 2026, 2:06 PM EDT
Completed Phase 2 Interventional Results available

Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder

NCT00722553
View directory record Official record
Conditions
Carcinoma, Transitional Cell, Bladder Cancer, Bladder Neoplasm
Interventions
Pralatrexate Injection, Vitamin B12, Folic Acid
Drug · Dietary Supplement
Lead sponsor
Acrotech Biopharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
4
States / cities
Tucson, Arizona • Atlanta, Georgia • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 23, 2026, 2:06 PM EDT
Completed Phase 3 Interventional Results available

MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma

NCT00094653
View directory record Official record
Conditions
Melanoma, Metastases
Interventions
MDX-010 (anti-CTLA4) monoclonal antibody, MDX-1379 (gp100) Melanoma Peptide Vaccine
Drug · Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,783 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
110
States / cities
Tucson, Arizona • Duarte, California • Encinitas, California + 78 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2011 · Synced Oct 23, 2026, 2:06 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

BRIDGE Device for Treatment of Opioid Withdrawal

NCT04162145
View directory record Official record
Conditions
Opioid Withdrawal, Pain, Craving
Interventions
Active BRIDGE device placement, Inactive BRIDGE device placement
Device
Lead sponsor
BrightView LLC
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 25, 2020 · Synced Oct 23, 2026, 2:06 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Compare Different Doses of RO7795081 With Placebo or Semaglutide in People With Type 2 Diabetes

NCT07112872
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
RO7795081, Semaglutide, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
21
States / cities
Tucson, Arizona • Lake Forest, California • Rancho Cucamonga, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 23, 2026, 2:06 PM EDT
Completed Early Phase 1 Interventional

TP-0903 for the Treatment of FLT3 Mutated Acute Myeloid Leukemia

NCT04518345
View directory record Official record
Conditions
Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia
Interventions
Azacitidine, Dubermatinib
Drug
Lead sponsor
Uma Borate
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 6, 2023 · Synced Oct 23, 2026, 2:06 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

TREAT-BE Study (Treatment With Resection and Endoscopic Ablation Techniques for Barrett's Esophagus)

NCT02634645
View directory record Official record
Conditions
Barrett's Esophagus, Esophageal Cancer
Interventions
Endoscopic eradication therapies (EET), Esophagectomy, Chemotherapy, Radiation
Procedure · Drug · Radiation
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2027
U.S. locations
4
States / cities
Los Angeles, California • Tampa, Florida • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2025 · Synced Oct 23, 2026, 2:06 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Scanadu Consumer Health Outcomes (SCOUT) Study

NCT02134145
View directory record Official record
Conditions
Disorder Characterized by Fever
Interventions
Not listed
Lead sponsor
Scripps Translational Science Institute
Other
Eligibility
19 Years and older
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Oct 23, 2026, 2:06 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Using Ultrasound to Study Respiratory Muscle Function in Critically Ill Patients

NCT03139695
View directory record Official record
Conditions
Injury of Diaphragm, Mechanical Ventilation Complication, Critical Illness
Interventions
Ultrasound
Diagnostic Test
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Oct 23, 2026, 2:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Possible Effects on the QTc Interval of CHF 4226 pMDI in Healthy Volunteers

NCT00777595
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
CHF 4226 pMDI, Placebo, Moxifloxacin
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
18 Years to 55 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Mar 27, 2009 · Synced Oct 23, 2026, 2:06 PM EDT
Completed Not applicable Interventional Results available

Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma

NCT01005745
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Surgery, Administration of Lymphodepletion, Adoptive Cell Transfer, High Dose IL-2
Procedure · Drug · Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2025
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 23, 2026, 2:06 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Effect of Exercise and Education After Pneumonia

NCT01744145
View directory record Official record
Conditions
Pneumonia
Interventions
Interventional 40-60, Interventional 60 and above
Other
Lead sponsor
Winthrop University Hospital
Other
Eligibility
40 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 23, 2026, 2:06 PM EDT
Completed Early Phase 1 Interventional

A Feasibility Trial of OCM Supplements for the Treatment of NAFLD

NCT05720702
View directory record Official record
Conditions
NAFLD
Interventions
homocysteine (Hcy) lowering supplements
Dietary Supplement
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 27, 2024 · Synced Oct 23, 2026, 2:06 PM EDT
Completed Phase 3 Interventional

A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body

NCT05568095
View directory record Official record
Conditions
Advanced Upper Gastrointestinal Tract Adenocarcinoma
Interventions
Domvanalimab, Zimberelimab, Capecitabine, Fluorouracil, Leucovorin, Oxaliplatin, Nivolumab
Drug
Lead sponsor
Arcus Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,040 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
31
States / cities
Los Angeles, California • Orange, California • Santa Monica, California + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 23, 2026, 2:06 PM EDT
Recruiting Phase 3 Interventional

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

NCT06064877
View directory record Official record
Conditions
Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Interventions
Ficlatuzumab, Cetuximab, Placebo
Biological · Other
Lead sponsor
AVEO Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
28
States / cities
Gilbert, Arizona • Tucson, Arizona • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 23, 2026, 2:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Audit-and-feedback to Improve Antimicrobial-prescribing Among Urologists

NCT04196777
View directory record Official record
Conditions
Urologic Diseases, Antibacterial Drug Adverse Reaction
Interventions
Audit-and-feedback
Behavioral
Lead sponsor
Iowa City Veterans Affairs Medical Center
Federal
Eligibility
Not listed
Enrollment
525 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
3
States / cities
Gainesville, Florida • Iowa City, Iowa • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 23, 2026, 2:06 PM EDT
Active, not recruiting Phase 2 Interventional

A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema

NCT06007677
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
STAR-0215
Drug
Lead sponsor
Astria Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
12
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Oct 23, 2026, 2:06 PM EDT
Completed Phase 2Phase 3 Interventional

Efficacy and Long-Term Safety of Vildagliptin as Monotherapy in Patients With Type 2 Diabetes

NCT00821977
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Vildagliptin, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
141
States / cities
Pell City, Alabama • Gilbert, Arizona • Mesa, Arizona + 116 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 23, 2026, 2:06 PM EDT
Completed Phase 3 Interventional Results available

Efficacy Study of Pioglitazone Compared to Glimepiride on Coronary Atherosclerotic Disease Progression in Subjects With Type 2 Diabetes Mellitus

NCT00225277
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Pioglitazone, Glimepiride
Drug
Lead sponsor
Takeda
Industry
Eligibility
35 Years to 85 Years
Enrollment
547 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
65
States / cities
Birmingham, Alabama • Phoenix, Arizona • Huntington Beach, California + 62 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2012 · Synced Oct 23, 2026, 2:06 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Allogeneic Mesenchymal Human Stem Cell Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects With Symptomatic Ischemic Heart Disease. (ACESO-IHD)

NCT04776239
View directory record Official record
Conditions
Diabetes Mellitus, Ischemic Heart Disease
Interventions
100 million Allogeneic Mesenchymal Human Stem Cells, Placebo
Drug · Other
Lead sponsor
Joshua M Hare
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 23, 2026, 2:06 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Feasibility Study of a Percutaneous Mitral Valve Repair System.

NCT00209339
View directory record Official record
Conditions
Mitral Valve Insufficiency, Mitral Valve Regurgitation, Mitral Valve Incompetence, Mitral Regurgitation, Mitral Insufficiency
Interventions
Percutaneous mitral valve repair (MitraClip Implant)
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Oct 23, 2026, 2:06 PM EDT